Drug Profile
Research programme: LG914 inhibitors - Amgen/Lexicon Genetics
Alternative Names: LG914 inhibitors research programme - Abgenix/Lexicon GeneticsLatest Information Update: 02 May 2007
Price :
$50
*
At a glance
- Originator Amgen; Lexicon Genetics
- Developer Amgen; Lexicon Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis
Most Recent Events
- 02 May 2007 Discontinued - Preclinical for Atherosclerosis in USA (unspecified route)
- 03 Apr 2006 Abgenix has been acquired and merged into Amgen
- 07 Sep 2005 This programme is still in active development